Invention Grant
- Patent Title: Compounds inhibiting leucine-rich repeat kinase enzyme activity
-
Application No.: US14772589Application Date: 2014-02-27
-
Publication No.: US09440952B2Publication Date: 2016-09-13
- Inventor: Michael Miller , Kallol Basu , Duane DeMong , Jack Scott , Hong Liu , Xing Dai , Joel M. Harris , Bernard Neustadt , Andrew Stamford , Marc Poirier , John A. McCauley , Thomas Greshock , Heather Stevenson , John Sanders , Jonathan Kern
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Keith D. MacMillan; John C. Todaro
- International Application: PCT/US2014/018929 WO 20140227
- International Announcement: WO2014/137728 WO 20140912
- Main IPC: C07D401/04
- IPC: C07D401/04 ; C07D401/14 ; C07D405/14 ; C07D409/14 ; C07D413/14 ; C07D417/14 ; C07D471/10 ; C07D451/02 ; C07D487/10 ; C07D491/04 ; C07D491/08 ; C07D491/056 ; C07D498/04 ; C07D498/08 ; C07D403/04 ; C07D491/10 ; C07D487/04 ; C07D491/107 ; C07D491/113
Abstract:
The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Public/Granted literature
- US20160009682A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY Public/Granted day:2016-01-14
Information query
